Xcell Therapeutics엑셀세라퓨틱스
373110 · KOSDAQ · ₩373110 · 엑셀세라퓨틱스
₩973▼ ₩25 (2.51%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Gross margin | −43.2% | −100.3% | −71.9% | −165.2% |
| Operating margin | −259.4% | −556.8% | −482.3% | −774.6% |
| Net margin | −260.9% | −560.7% | −493.4% | −825.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Revenue growth | +123.5% | +0.8% | +72.1% | — |
| Operating income growth | −4.1% | −16.3% | −7.2% | — |
| Net income growth | −4.0% | −14.5% | −2.8% | — |
Returns
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Return on equity | −198.3% | −134.4% | −165.9% | −389.4% |
| Return on assets | −80.2% | −67.0% | −69.8% | −88.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Liabilities to equity | 191.9% | 120.2% | 85.2% | 339.2% |
| Net debt to equity | 8.0% | 31.4% | −33.4% | 162.0% |
| Current ratio | 127.8% | 180.7% | 214.2% | 81.2% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Xcell Therapeutics / 엑셀세라퓨틱스 / 373110 / KRX:373110
Source: KRX statistical information